Home – Referenties

REALISATIES

+30 jaar ervaring met klinische studies en onderzoeken

Gedurende meer dan 30 jaar heeft ons centrum een verscheidenheid aan studies uitgevoerd in verschillende therapeutische indicaties maar vooral gespecialiseerd in aandoeningen van de hersenen.

Door de uitbreiding van onze faciliteiten, eerst in 2017 en vervolgens in 2021 met heden 2 volledig uitgeruste locaties enerzijds te Alken (Alkerstraat 28-30-30A-32Z) en anderzijds te Diepenbeek (Wetenschapspark 11-13), heeft ARC momenteel een zeer uitgebreide klinische onderzoeksfaciliteit, beantwoordend aan de meest strenge internationale vereisten.

Met onder meer een dag- en nachtverblijf voor 12 personen dewelke toelaat om intensieve PK sampling uit te voeren alsook andere veeleisende klinische evaluaties zoals poly-somnografie (PSG) kan Anima Research Center de meest veeleisende Phase 0 tot en met Phase IV studies uitvoeren.

Interesse in een samenwerking?

Contacteer Anima

+2600

Actuele deelnemers in klinische studie

+10.000

Gekwalificeerde patiënten in onze database

+10

Strategische samenwerkingen met internationaal actieve pharmabedrijven

5

Toponderzoekers

RESULTATEN

+50 Clinical studies

1989-1990: Phase III trial investigating mianserine

2000-2001: phase III trial investigating agomelatine

2001-2002: phase III trial investigating escitalopram

2003-2005: phase III and 1 phase IIb trial: several NK1-Antagonists

2006-2013: 5 phase I trials, 1 phase II trial and 1 phase III trial investigating PNB01

2014- ongoing :

3 Phase III trials & 1 Phase IV trial investigating esketamine in Treatment Resistant Depression, 1 Recruitment still ongoing.
2 Phase 0 bio-marker study in healthy volunteers and depressed patients with and without intake of antidepressants.
1 Phase I trial investigating impact of seltoxerant on driving capabilities. Highest recruiter wordwide. Successfully audited by sponsor Janssen Pharmaceutica.
1 Phase III trials investigating aticaprant as adjunctive treatment in Major Depression.

1991-1992: phase IIa trial investigating cycloserine in cognitive impairment

2020 – ongoing: Phase I On Road Driving Study investigating cognitive impact of seltorexant in patients with Major Depressive Disorder. Recruitment Ongoing.

2021: Phase 0 bio-marker study in patients with a neurodegenerative disorder

2022: Phase IIa study in neuro-degeneration in Mild Cognitive Impairment, Parkinson and Alzheimer Disease

1987-1988: phase III trial investigating Risperidone

2004: phase III trial investigating aripiprazole

2006-2007: phase III trial investigating asenapine

2013: phase IIa trial investigating PNB02 in treatment resistant schizophrenia

2004-2005: phase IIb trial investigating gaboxadol in primary insomnia.

2018-2019: phase IIb trial investigating seltorexant including PSG and cognitive test battery assessments. Highest recruiter in Belgium. Successfully audited by the sponsor Janssen Pharmaceutica.

2019-2020: phase III clinical study investigating JZP-080 in idiopathic hypersomnia including specialized narcotics handling & PSG and MSLT assessments. Highest recruiter of Europe. Successfully audited by the sponsor Jazz Pharmaceuticals.

2022 – ongoing: Phase II clinical study investigating undisclosed compound in Obstructive Sleep Apnoe. Highest Recruiter worldwide.

1993-1994: Phase III trial investigating sertraline in obsessive-compulsive disorder

2021 – ongoing: Phase 0 bio-marker study in PTSD patients with and without intake of psychotropics

2021 – ongoing: Phase 0 bio-marker study in bipolar patients with and without intake of psychotropics

2020 – ongoing: 3 Phase III trial investigating antibody treatment to prevent COVID-19 infection in high risk and elderly population. Recruitment ongoing.

2020 – ongoing: 3 phase III trial investigating vaccine to prevent COVID-19 infections. Highest recruiter worldwide in one key study.

2020 – 2022: phase I/IIA trial investigating vaccine to prevent septic shock in patients with medical history of UTI. Recruitment closed. Highest recruiter!

2021 – ongoing: 3 phase I-III trials investigating vaccine to prevent RSV infections. Recruitment closed. Highest recruiter in Belgium.

2022 – ongoing: Phase III trials investigating an innovative pneumococcal vaccine. Highest recruiter worldwide.

2023 – planned: Fist in Human Study with innovative HPV vaccine (selected).

2023 – planned: Phase II-III clinical trial with innovative meningococcal vaccine (selected).

2022 – ongoing: Phase I clincal trial with innovative immunoregulating compound for treatment of atopic dermatitis. Highest recruiter worldwide.

2022-ongoing: Phase I Safety & Pharmaco-dynamic clincal trial, including high end imaging (MRI, US) with innovative combination drug in prevention of sarcopenia. Selected as single study center for this very high demanding clincal study.